225 related articles for article (PubMed ID: 31388911)
1. An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature.
Pallazola VA; Deib G; Abha S; Geha RM; Kobayashi K
J Gen Intern Med; 2019 Nov; 34(11):2669-2674. PubMed ID: 31388911
[TBL] [Abstract][Full Text] [Related]
2. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
3. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
[TBL] [Abstract][Full Text] [Related]
4. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
5. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
[TBL] [Abstract][Full Text] [Related]
6. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
[No Abstract] [Full Text] [Related]
7. Brentuximab vedotin in CD30
Enos TH; Feigenbaum LS; Wickless HW
Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
[TBL] [Abstract][Full Text] [Related]
8. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
Goyal A; Hordinsky M; Lazaryan A
Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
[TBL] [Abstract][Full Text] [Related]
9. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
10. Dramatic response to brentuximab vedotin in refractory nontransformed CD30
Mahévas T; Ram-Wolff C; Battistella M; Pennamen MDV; Rivet J; Brice P; Bagot M
Br J Dermatol; 2019 Jun; 180(6):1517-1520. PubMed ID: 30269331
[TBL] [Abstract][Full Text] [Related]
11. Erythroderma with brentuximab vedotin in a patient with mycosis fungoides.
Kakurai M; Oya K; Ishizuki S; Suehara Y; Nomura T
Eur J Dermatol; 2023 Apr; 33(2):167-168. PubMed ID: 37431123
[No Abstract] [Full Text] [Related]
12. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
13. Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin.
Zhang C; Chairatchaneeboon M; Haun P; Landsburg D; Kim EJ
JAMA Dermatol; 2018 Jan; 154(1):109-110. PubMed ID: 29167875
[No Abstract] [Full Text] [Related]
14. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
15. Mycosis fungoides presenting as pigmented purpuric dermatitis.
Hanna S; Walsh N; D'Intino Y; Langley RG
Pediatr Dermatol; 2006; 23(4):350-4. PubMed ID: 16918631
[TBL] [Abstract][Full Text] [Related]
16. Guttate psoriasis in a patient with mycosis fungoides in treatment with Brentuximab vedotin: An unreported association.
Roccuzzo G; Cavallo F; Avallone G; Fava P; Conti L; Ribero S; Fierro MT; Quaglino P
Dermatol Ther; 2022 Apr; 35(4):e15309. PubMed ID: 35000253
[No Abstract] [Full Text] [Related]
17. Histologic mimickers of mycosis fungoides: a review.
Reddy K; Bhawan J
J Cutan Pathol; 2007 Jul; 34(7):519-25. PubMed ID: 17576330
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
